Educational Wellness Information Only
This platform provides peer-reviewed research summaries and educational content about peptides for wellness and optimization purposes. Nothing on this site is intended as medical advice, diagnosis, or treatment. We do not claim any peptide can diagnose, treat, cure, or prevent any disease. Always consult a licensed healthcare provider before beginning any wellness protocol.
Statements on this site have not been evaluated by the FDA. Compounded preparations are subject to applicable state and federal regulations. Availability and eligibility vary.
Dihexa vs P21
An educational, source-based comparison of Dihexa and P21 — how each peptide works, what it's researched for, and what to know before going deeper.
A hexapeptide derived from angiotensin IV that crosses the blood-brain barrier and potentiates hepatocyte growth factor (HGF) / c-Met signaling, associated with new synapse formation in preclinical models.
- Synaptogenesis and dendritic spine density
- Alzheimer's and cognitive aging models
- Memory consolidation in rodents
- • No human clinical trial data; theoretical proliferation concerns via HGF/c-Met.
- • Not FDA-approved.
A synthetic peptide derived from cerebrolysin. Research suggests it promotes synaptic plasticity by enhancing BDNF expression and inhibiting prolyl endopeptidase, an enzyme involved in neurodegenerative processes.
- Synaptic plasticity and memory
- Neuroprotection in Alzheimer's models
- Cognitive recovery after brain injury
- • Experimental; limited human data available.
- • Not FDA-approved.
Dihexa vs P21 — Key differences
- Class: Dihexa is classified as Nootropic · Synaptogenesis, while P21 is Nootropic · Neuroprotection.
- Primary research focus: Dihexa — synaptogenesis and dendritic spine density; P21 — synaptic plasticity and memory.
- Tag: Cognition vs Cognition · Neuroprotection.